Switch theme
Sign up to access all valuation multiples
EKF Diagnostics Holdings PLC is engaged in development, manufacture and supply of products and services into the in-vitro diagnostic (IVD) market place. The Group has presence in the UK, USA, Germany, and Russia, and sells throughout the world including Europe, the Middle East, the Americas, Asia, and Africa. It derive their revenue from the manufacture and sale of medical diagnostic equipment and reagents. Other services include the servicing and distribution of third party company products under separate distribution agreements.
2002
303
LTM Revenue $69.1M
LTM EBITDA $15.8M
$137M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
EKF Diagnostics has a last 12-month revenue (LTM) of $69.1M and a last 12-month EBITDA of $15.8M.
In the most recent fiscal year, EKF Diagnostics achieved revenue of $67.4M and an EBITDA of $15.0M.
EKF Diagnostics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See EKF Diagnostics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $69.1M | XXX | $67.4M | XXX | XXX | XXX |
| Gross Profit | $33.8M | XXX | $32.3M | XXX | XXX | XXX |
| Gross Margin | 49% | XXX | 48% | XXX | XXX | XXX |
| EBITDA | $15.8M | XXX | $15.0M | XXX | XXX | XXX |
| EBITDA Margin | 23% | XXX | 22% | XXX | XXX | XXX |
| EBIT | $10.1M | XXX | $8.4M | XXX | XXX | XXX |
| EBIT Margin | 15% | XXX | 13% | XXX | XXX | XXX |
| Net Profit | $8.2M | XXX | $8.4M | XXX | XXX | XXX |
| Net Margin | 12% | XXX | 12% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, EKF Diagnostics's stock price is GBP 0 (or $0).
EKF Diagnostics has current market cap of GBP 114M (or $153M), and EV of GBP 102M (or $137M).
See EKF Diagnostics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $137M | $153M | XXX | XXX | XXX | XXX | $0.02 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, EKF Diagnostics has market cap of $153M and EV of $137M.
EKF Diagnostics's trades at 2.0x EV/Revenue multiple, and 9.1x EV/EBITDA.
Equity research analysts estimate EKF Diagnostics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
EKF Diagnostics has a P/E ratio of 18.7x.
See valuation multiples for EKF Diagnostics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $153M | XXX | $153M | XXX | XXX | XXX |
| EV (current) | $137M | XXX | $137M | XXX | XXX | XXX |
| EV/Revenue | 2.0x | XXX | 2.0x | XXX | XXX | XXX |
| EV/EBITDA | 8.7x | XXX | 9.1x | XXX | XXX | XXX |
| EV/EBIT | 13.5x | XXX | 16.2x | XXX | XXX | XXX |
| EV/Gross Profit | 4.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | 18.7x | XXX | 18.2x | XXX | XXX | XXX |
| EV/FCF | 12.4x | XXX | 9.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialEKF Diagnostics's last 12 month revenue growth is 7%
EKF Diagnostics's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
EKF Diagnostics's rule of 40 is 21% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
EKF Diagnostics's rule of X is 40% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for EKF Diagnostics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 7% | XXX | 7% | XXX | XXX | XXX |
| EBITDA Margin | 23% | XXX | 22% | XXX | XXX | XXX |
| EBITDA Growth | 11% | XXX | 27% | XXX | XXX | XXX |
| Rule of 40 | 21% | XXX | 29% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 40% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 35% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
EKF Diagnostics acquired XXX companies to date.
Last acquisition by EKF Diagnostics was XXXXXXXX, XXXXX XXXXX XXXXXX . EKF Diagnostics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was EKF Diagnostics founded? | EKF Diagnostics was founded in 2002. |
| Where is EKF Diagnostics headquartered? | EKF Diagnostics is headquartered in United Kingdom of Great Britain and Northern Ireland. |
| How many employees does EKF Diagnostics have? | As of today, EKF Diagnostics has 303 employees. |
| Who is the CEO of EKF Diagnostics? | EKF Diagnostics's CEO is Mr. Gavin Joseph Jones. |
| Is EKF Diagnostics publicy listed? | Yes, EKF Diagnostics is a public company listed on LON. |
| What is the stock symbol of EKF Diagnostics? | EKF Diagnostics trades under EKF ticker. |
| When did EKF Diagnostics go public? | EKF Diagnostics went public in 2002. |
| Who are competitors of EKF Diagnostics? | Similar companies to EKF Diagnostics include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of EKF Diagnostics? | EKF Diagnostics's current market cap is $153M |
| What is the current revenue of EKF Diagnostics? | EKF Diagnostics's last 12 months revenue is $69.1M. |
| What is the current revenue growth of EKF Diagnostics? | EKF Diagnostics revenue growth (NTM/LTM) is 7%. |
| What is the current EV/Revenue multiple of EKF Diagnostics? | Current revenue multiple of EKF Diagnostics is 2.0x. |
| Is EKF Diagnostics profitable? | Yes, EKF Diagnostics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of EKF Diagnostics? | EKF Diagnostics's last 12 months EBITDA is $15.8M. |
| What is EKF Diagnostics's EBITDA margin? | EKF Diagnostics's last 12 months EBITDA margin is 23%. |
| What is the current EV/EBITDA multiple of EKF Diagnostics? | Current EBITDA multiple of EKF Diagnostics is 8.7x. |
| What is the current FCF of EKF Diagnostics? | EKF Diagnostics's last 12 months FCF is $11.1M. |
| What is EKF Diagnostics's FCF margin? | EKF Diagnostics's last 12 months FCF margin is 16%. |
| What is the current EV/FCF multiple of EKF Diagnostics? | Current FCF multiple of EKF Diagnostics is 12.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
